Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 152

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 152
---
 audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the Consolidated Financial Statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations, or cash flows.

87

Table of Contents

Earnings Per ShareBasic earnings per share ("EPS") is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:Years Ended December 31,(in millions)202420232022Denominator:Weighted-average shares outstanding used to compute basic EPS90.6 82.8 80.6 Effect of dilutive stock options and RSUs— — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS90.6 82.8 80.6 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Years Ended December 31,(in millions)202420232022Anti-dilutive options and RSUs excluded from EPS computation6.0 5.1 4.4 Foreign CurrencyThe functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity.The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):Ending balance December 31, 2023$(3.7)Period translation adjustments(3.0)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax5.9 Ending balance December 31, 2024$(0.8)During the years ended December 31, 2024 and 2023, the Company recognized losses related to foreign currency of $1.1 million and $3.4 million, respectively, which is included in Other in the Consolid